Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Parkinson's Disease, the Dopaminergic Neuron and Gammahydroxybutyrate.

Mamelak M.

Neurol Ther. 2018 Jun;7(1):5-11. doi: 10.1007/s40120-018-0091-2. Epub 2018 Jan 24.

2.

Correlation of Changes in Patient-Reported Quality of Life With Physician-Rated Global Impression of Change in Patients With Narcolepsy Participating in a Clinical Trial of Sodium Oxybate: A Post Hoc Analysis.

Bogan RK, Black J, Swick T, Mamelak M, Kovacevic-Ristanovic R, Villa KF, Mori F, Montplaisir J.

Neurol Ther. 2017 Dec;6(2):237-245. doi: 10.1007/s40120-017-0076-6. Epub 2017 Jul 13.

3.

Energy and the Alzheimer brain.

Mamelak M.

Neurosci Biobehav Rev. 2017 Apr;75:297-313. doi: 10.1016/j.neubiorev.2017.02.001. Epub 2017 Feb 11. Review.

PMID:
28193453
4.

Evaluation of Quality of Life in Patients With Narcolepsy Treated With Sodium Oxybate: Use of the 36-Item Short-Form Health Survey in a Clinical Trial.

Bogan R, Swick T, Mamelak M, Kovacevic-Ristanovic R, Lai C, Black J, Villa KF, Montplaisir J.

Neurol Ther. 2016 Dec;5(2):203-213. Epub 2016 Oct 24.

5.

Metabolic effects of eradicating breath methane using antibiotics in prediabetic subjects with obesity.

Mathur R, Chua KS, Mamelak M, Morales W, Barlow GM, Thomas R, Stefanovski D, Weitsman S, Marsh Z, Bergman RN, Pimentel M.

Obesity (Silver Spring). 2016 Mar;24(3):576-82. doi: 10.1002/oby.21385. Epub 2016 Feb 1.

6.

A 12-week open-label, multicenter study evaluating the safety and patient-reported efficacy of sodium oxybate in patients with narcolepsy and cataplexy.

Mamelak M, Swick T, Emsellem H, Montplaisir J, Lai C, Black J.

Sleep Med. 2015 Jan;16(1):52-8. doi: 10.1016/j.sleep.2014.10.004. Epub 2014 Oct 22.

7.

Sporadic Alzheimer's disease: the starving brain.

Mamelak M.

J Alzheimers Dis. 2012;31(3):459-74. doi: 10.3233/JAD-2012-120370. Review.

PMID:
22571985
8.

Narcolepsy and depression and the neurobiology of gammahydroxybutyrate.

Mamelak M.

Prog Neurobiol. 2009 Oct;89(2):193-219. doi: 10.1016/j.pneurobio.2009.07.004. Epub 2009 Aug 3. Review.

PMID:
19654034
9.

Alzheimer' s disease, oxidative stress and gammahydroxybutyrate.

Mamelak M.

Neurobiol Aging. 2007 Sep;28(9):1340-60. Epub 2006 Jul 11. Review.

PMID:
16837107
10.

A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy.

Mamelak M, Black J, Montplaisir J, Ristanovic R.

Sleep. 2004 Nov 1;27(7):1327-34.

PMID:
15586785
11.

The motor vehicle collision injury syndrome.

Mamelak M.

Neuropsychiatry Neuropsychol Behav Neurol. 2000 Apr;13(2):125-35. Review.

PMID:
10780631
12.

Effects of aging on the useful field of view.

Sekuler AB, Bennett PJ, Mamelak M.

Exp Aging Res. 2000 Apr-Jun;26(2):103-20.

PMID:
10755218
13.

Neurodegeneration, sleep, and cerebral energy metabolism: a testable hypothesis.

Mamelak M.

J Geriatr Psychiatry Neurol. 1997 Jan;10(1):29-32. Review.

PMID:
9100156
14.

Narcolepsy secondary to fourth ventricular subependymoma.

Ma TK, Ang LC, Mamelak M, Kish SJ, Young B, Lewis AJ.

Can J Neurol Sci. 1996 Feb;23(1):59-62.

PMID:
8673965
15.

Morphometry of reversible myocardial damage.

Kolin A, Brezina A, Mamelak M, Pandula E.

Ann N Y Acad Sci. 1994 Jun 17;723:396-7. No abstract available.

PMID:
8030894
16.

Cardioprotective action of sodium gamma-hydroxybutyrate against isoproterenol induced myocardial damage.

Kolin A, Brezina A, Mamelak M, Pandula E.

Int J Exp Pathol. 1993 Jun;74(3):275-81.

17.

High- and low-affinity states of dopamine D1 receptors in schizophrenia.

Mamelak M, Chiu S, Mishra RK.

Eur J Pharmacol. 1993 Mar 16;233(1):175-6.

PMID:
8472745
18.

A perspective on narcolepsy.

Mamelak M.

Encephale. 1992 Jul-Aug;18(4):347-51.

PMID:
1338429
19.

Brain neurotransmitter changes in human narcolepsy.

Kish SJ, Mamelak M, Slimovitch C, Dixon LM, Lewis A, Shannak K, DiStefano L, Chang LJ, Hornykiewicz O.

Neurology. 1992 Jan;42(1):229-34.

PMID:
1370862
20.

Cardioprotective effects of sodium gamma-hydroxybutyrate (GHB) on brain induced myocardial injury.

Kolin A, Brezina A, Mamelak M.

In Vivo. 1991 Jul-Aug;5(4):429-31.

PMID:
1810434
21.

A model for narcolepsy.

Mamelak M.

Can J Psychol. 1991 Jun;45(2):194-220. Review.

PMID:
1651801
22.

The protective effect of gamma-hydroxybutyrate in regional intestinal ischemia in the hamster.

Boyd AJ, Sherman IA, Saibil FG, Mamelak M.

Gastroenterology. 1990 Sep;99(3):860-2.

PMID:
2379790
23.

Clinical recovery and sleep architecture degradation.

Hachinski VC, Mamelak M, Norris JW.

Can J Neurol Sci. 1990 Aug;17(3):332-5.

PMID:
2207892
24.

The effects of a single night's dosing with triazolam on sleep the following night.

Mamelak M, Csima A, Price V.

J Clin Pharmacol. 1990 Jun;30(6):549-55.

PMID:
2355105
25.

Psychological, topographic EEG, and CT scan correlates of frontal lobe function in schizophrenia.

Williamson PC, Kutcher SP, Cooper PW, Snow WG, Szalai JP, Kaye H, Morrison SL, Willinsky RA, Mamelak M.

Psychiatry Res. 1989 Aug;29(2):137-49.

PMID:
2798593
26.

A comparative study on the effects of brotizolam and flurazepam on sleep and performance in the elderly.

Mamelak M, Csima A, Buck L, Price V.

J Clin Psychopharmacol. 1989 Aug;9(4):260-7.

PMID:
2671059
27.

Gammahydroxybutyrate: an endogenous regulator of energy metabolism.

Mamelak M.

Neurosci Biobehav Rev. 1989 Winter;13(4):187-98. Review.

PMID:
2691926
28.

Serum and quantitative electroencephalographic pharmacokinetics of loprazolam in the elderly.

Mamelak M, Bunting P, Galin H, Price V, Csima A, Young T, Klein D, Pelchat JR.

J Clin Pharmacol. 1988 Apr;28(4):376-83.

PMID:
3392236
29.

Frontal spectral EEG findings in acutely ill schizophrenics.

Williamson P, Mamelak M.

Biol Psychiatry. 1987 Aug;22(8):1021-4. No abstract available.

PMID:
3607126
30.
31.

Spectral EEG correlates of dream recall.

Williamson PC, Csima A, Galin H, Mamelak M.

Biol Psychiatry. 1986 Jul;21(8-9):717-23.

PMID:
3730456
32.
33.

Brain adenylate cyclase activity in the amphetamine sensitized rat.

Mamelak M, Chiu S, Mishra R.

Prog Neuropsychopharmacol Biol Psychiatry. 1985;9(5-6):721-4.

PMID:
4089198
34.

Effects of quazepam and triazolam on the sleep of chronic insomniacs: a comparative 25-night sleep laboratory study.

Mamelak M, Csima A, Price V.

Clin Neuropharmacol. 1985;8 Suppl 1:S63-73. No abstract available.

PMID:
3837688
35.

A comparative 25-night sleep laboratory study on the effects of quazepam and triazolam on chronic insomniacs.

Mamelak M, Csima A, Price V.

J Clin Pharmacol. 1984 Feb-Mar;24(2-3):65-75.

PMID:
6143767
36.

The effect of gammahydroxybutyrate on the H-reflex: pilot study.

Mamelak M, Sowden K.

Neurology. 1983 Nov;33(11):1497-500.

PMID:
6314181
37.

Effects of brotizolam on the sleep of chronic insomniacs.

Mamelak M, Csima A, Price V.

Br J Clin Pharmacol. 1983;16 Suppl 2:377S-382S.

38.

Effects of zopiclone on the sleep of chronic insomniacs.

Mamelak M, Scima A, Price V.

Pharmacology. 1983;27 Suppl 2:156-64.

PMID:
6366819
39.

Effects of zopiclone on the sleep of chronic insomniacs.

Mamelak M, Scima A, Price V.

Int Pharmacopsychiatry. 1982;17 Suppl 2:156-64.

PMID:
7188373
41.

Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy.

Broughton R, Mamelak M.

Can J Neurol Sci. 1980 Feb;7(1):23-31.

PMID:
7388696
42.

Narcolepsy: a family study.

Mamelak M, Caruso VJ, Stewart K.

Biol Psychiatry. 1979 Oct;14(5):821-34.

PMID:
227489
43.

The treatment of narcolepsy-cataplexy with nocturnal gamma-hydroxybutyrate.

Broughton R, Mamelak M.

Can J Neurol Sci. 1979 Feb;6(1):1-6.

PMID:
264152
45.

An amphetamine model of manic depressive illness.

Mamelak M.

Int Pharmacopsychiatry. 1978;13(4):193-208. Review.

PMID:
215569
46.

The effects of gamma-hydroxybutyrate on sleep.

Mamelak M, Escriu JM, Stokan O.

Biol Psychiatry. 1977 Apr;12(2):273-88.

PMID:
192353
47.

Sleep-inducing effects of gammahydroxybutyrate.

Mamelak M, Escriu JM, Stokan O.

Lancet. 1973 Aug 11;2(7824):328-9. No abstract available.

PMID:
4124818
48.

Vasopressin: possible role of microtubules and microfilaments in its action.

Taylor A, Mamelak M, Reaven E, Maffly R.

Science. 1973 Jul 27;181(4097):347-50.

PMID:
4352609
49.

Effect of chlorpromazine on permeability of the toad bladder.

Mamelak M, Weissbluth M, Maffly RH.

Biochem Pharmacol. 1970 Jul;19(7):2303-15. No abstract available.

PMID:
4329040
50.

Physiological and morphological effects of poly-L-lysine on the toad bladder.

Mamelak M, Wissig SL, Bogoroch R, Edelman IS.

J Membr Biol. 1969 Dec;1(1):144-76. doi: 10.1007/BF01869779.

PMID:
24174047

Supplemental Content

Loading ...
Support Center